PD-1 / PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Se han encontrado 125 productos de "PD-1 / PD-L1"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Camrelizumab
CAS:<p>Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up</p>Pureza:95% - 98.6%Forma y color:LiquidPeso molecular:143.7 kDaLipustobart
CAS:<p>Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplastic</p>Pureza:98%Forma y color:LiquidPidilizumab
CAS:<p>Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic</p>Pureza:98%Forma y color:LiquidNofazinlimab
CAS:<p>Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody for the study of unresectable hepatocellular carcinoma (uHCC).</p>Pureza:98.6% (SDS-PAGE); 99.7% (SEC-HPLC) - 98.6% (SDS-PAGE); 99.7% (SEC-HPLC)Forma y color:LiquidLatikafusp
CAS:<p>Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.</p>Pureza:97.1% (SDS-PAGE); 97.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 97.4% (SEC-HPLC)Forma y color:LiquidPacmilimab
CAS:<p>Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.</p>Pureza:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Forma y color:LiquidAcrixolimab
CAS:<p>Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].</p>Pureza:98%Forma y color:LiquidProlgolimab
CAS:<p>Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.</p>Pureza:>95%Forma y color:LiquidRetifanlimab
CAS:<p>Retifanlimab (MGA-012) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Retifanlimab is used in studies of Merkel cell carcinoma.</p>Pureza:95% - 98.56% (SEC-HPLC)Forma y color:LiquidAnti-Mouse PD-L1 Antibody (10F.9G2)
<p>Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.</p>Pureza:98.92% - >95% Determined by SDS-PAGEForma y color:Odour LiquidDanburstotug
CAS:<p>Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).</p>Pureza:98%Forma y color:LiquidARB-272572 hydrochloride
CAS:<p>ARB-272572 hydrochloride is a PD-L1 inhibitor that inhibits PD-1/PD-L1 cell signaling by inducing PD-L1 protein homology interactions.</p>Fórmula:C32H36N6O4·xClHPureza:99.38%Forma y color:SoildPeso molecular:568.68(Free base）IMMH 010 maleate
CAS:<p>IMMH 010 maleate (YPD-30 maleate) is a programmed cell death ligand 1 inhibitor used in the study of neurological disorders and advanced malignant solid tumors.</p>Fórmula:C36H36BrClN2O9Forma y color:SoildPeso molecular:756.04LP23
<p>LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/Jurkat</p>Fórmula:C27H27N3O5SPureza:98%Forma y color:SolidPeso molecular:505.59(D)-PPA 1 TFA
<p>(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstrating</p>Fórmula:C72H99F3N20O23Pureza:98%Forma y color:SolidPeso molecular:1669.67PD-1/PD-L1-IN-31
<p>PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood</p>Fórmula:C24H24ClFN2O3Pureza:98%Forma y color:SolidPeso molecular:442.91PD-1/PD-L1-IN-50
<p>Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.</p>Forma y color:Odour SolidPD-1/PD-L1-IN-51
<p>PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.</p>Forma y color:Odour SolidPD-1/PD-L1-IN-32
<p>PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM.</p>Pureza:98%Forma y color:Odour SolidPD-1/PD-L1-IN-52
<p>PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.</p>Forma y color:Odour Solid
